Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):643-9. doi: 10.1016/j.ijrobp.2012.06.033. Epub 2012 Jul 24.
To retrospectively evaluate institutional outcomes for patients treated with modern radiation therapy (RT) for biopsied orbital pseudotumor (OP).
Twenty patients (26 affected orbits) with OP were treated with RT between January 2002 and December 2011. All patients underwent biopsy with histopathologic exclusion of other disease processes. Sixteen patients (80%) were treated with intensity modulated RT, 3 (15%) with opposed lateral beams, and 1 (5%) with electrons. Median RT dose was 27 Gy (range 25.2-30.6 Gy). Response to RT was evaluated at 4 months post-RT. Partial response (PR) was defined as improvement in orbital symptoms without an increase in steroid dose. Complete response (CR) 1 and CR 2 were defined as complete resolution of orbital symptoms with reduction in steroid dose (CR 1) or complete tapering of steroids (CR 2). The median follow-up period was 18.6 months (range 4-81.6 months).
Seventeen patients (85%) demonstrated response to RT, with 7 (35%), 1 (5%), and 9 (45%) achieving a PR, CR 1, and CR 2, respectively. Of the 17 patients who had ≥ PR at 4 months post-RT, 6 (35%) experienced recurrence of symptoms. Age (>46 years vs ≤ 46 years, P=.04) and clinical response to RT (CR 2 vs CR 1/PR, P=.05) were significantly associated with pseudotumor recurrence. Long-term complications were seen in 7 patients (35%), including 4 with cataract formation, 1 with chronic dry eye, 1 with enophthalmos, and 1 with keratopathy.
RT is an effective treatment for improving symptoms and tapering steroids in patients with a biopsy supported diagnosis of OP. Older age and complete response to RT were associated with a significantly reduced probability of symptom recurrence. The observed late complications may be related to RT, chronic use of steroids/immunosuppressants, medical comorbidities, or combination of factors.
回顾性评估经现代放射治疗(RT)治疗活检眼眶假性肿瘤(OP)患者的机构治疗结果。
2002 年 1 月至 2011 年 12 月,20 例(26 只受累眼)OP 患者接受 RT 治疗。所有患者均行活检,组织病理学排除其他疾病过程。16 例(80%)患者接受调强放疗,3 例(15%)接受对侧侧位照射,1 例(5%)接受电子照射。中位 RT 剂量为 27Gy(范围 25.2-30.6Gy)。在 RT 后 4 个月评估 RT 反应。部分缓解(PR)定义为眼眶症状改善,而无需增加类固醇剂量。完全缓解(CR)1 和 CR2 定义为眼眶症状完全缓解,类固醇剂量减少(CR1)或完全停用类固醇(CR2)。中位随访时间为 18.6 个月(4-81.6 个月)。
17 例(85%)患者对 RT 有反应,7 例(35%)、1 例(5%)和 9 例(45%)分别获得 PR、CR1 和 CR2。在 17 例患者中,17 例(85%)在 RT 后 4 个月有≥PR,其中 6 例(35%)出现症状复发。年龄(>46 岁与≤46 岁,P=.04)和 RT 临床反应(CR2 与 CR1/PR,P=.05)与假性肿瘤复发显著相关。7 例(35%)患者出现长期并发症,包括 4 例白内障形成、1 例慢性干眼症、1 例眼球内陷和 1 例角膜病变。
RT 是改善症状和减少接受活检支持 OP 诊断的患者类固醇用量的有效治疗方法。年龄较大和对 RT 的完全反应与症状复发的可能性显著降低相关。观察到的迟发性并发症可能与 RT、长期使用类固醇/免疫抑制剂、医学合并症或多种因素有关。